In ovarian cancer, HDAC1 promotes cancer cell proliferation by increasing cyclin A (Hayashi et al., 2010), and HDAC2 interferes with cisplatin-induced activation of DNA damage responses by remodeling chromatin (Huang et al., 2016). The gene discussed is CCNA2; the disease is cancer.